Biotech Acquisition (OTCMKTS:BIOTU – Get Free Report) shares dropped 7.7% during mid-day trading on Friday . The company traded as low as $10.14 and last traded at $10.14. 1,300 shares changed hands during trading, a decline of 71% from the average daily volume of 4,444 shares. The stock had previously closed at $10.98.
Biotech Acquisition Price Performance
The company’s fifty day moving average is $10.14 and its 200 day moving average is $10.14.
Biotech Acquisition Company Profile
Biotech Acquisition (OTCMKTS: BIOTU) is a special purpose acquisition company organized in Delaware with the purpose of identifying, acquiring, or merging with one or more businesses in the life sciences sector. The company operates as a blank‐check vehicle, raising capital through its initial offering and placing proceeds in a trust until it completes a qualifying business combination. By focusing on biotechnology targets, Biotech Acquisition aims to leverage its structure and funding to support emerging companies in the development, commercialization, and distribution of novel therapeutics and diagnostics.
Since its formation, Biotech Acquisition has sought out opportunities across the United States and internationally, with an emphasis on firms that possess advanced research capabilities in areas such as oncology, gene therapy, and immunology.
Further Reading
- Five stocks we like better than Biotech Acquisition
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
